Navigation Links
Meso Scale Diagnostics' Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
Date:5/4/2009

GAITHERSBURG, Md., May 4 /PRNewswire/ -- Meso Scale Diagnostics, LLC. (MSD) confirmed today that its investigational influenza test was used in detecting the first identified case of infection with the 2009 A(H1N1) swine flu. The MSD(R) Point of Care Influenza Test, which is being developed under a contract with the Centers for Disease Control and Prevention (CDC), is the investigational device referred to in the CDC's Morbidity and Mortality Weekly Report (MMWR) Dispatch dated April 21, 2009.

As described in the MMWR Dispatch, Patient A visited an outpatient clinic in San Diego with influenza-like symptoms and participated in an ongoing clinical study of the MSD Point of Care Influenza Test, coordinated at that site by the Naval Health Research Center. A nasal swab taken from the patient tested positive for Influenza A on the MSD test, but the specific subtype could not be determined by the test, suggesting the possible presence of a novel influenza strain. Per protocols established for conducting the clinical trial, this result prompted further testing at a reference laboratory that confirmed that the virus was not a common seasonal strain. The virus was ultimately identified by the CDC as a novel strain that included components having swine influenza lineage.

MSD's Point of Care Influenza Test has been in development since 2006 under a contract with CDC, supported by the Biomedical Advanced Research and Development Authority (BARDA), an office under the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health & Human Services (HHS). MSD's test supports BARDA's goal of advancing rapid point-of-care diagnostic tests for novel influenza viruses. Currently-available point of care influenza tests are designed to detect influenza A and B infections. The MSD Point of Care Influenza Test is designed to additionally identify influenza A infections by subtype, differentiating between common human A(H1N1), common human A(H3N2) and avian A(H5N1) influenza strains.

The MSD Point of Care Influenza Test has been granted an investigational device exemption by the U.S. Food and Drug Administration and is currently undergoing evaluation in a multi-site clinical trial. The test, which consists of a portable instrument and disposable test cartridges, reports results from a nasal swab sample within 15 minutes. The early identification of the 2009 A(H1N1) swine flu infection as a result of the use of MSD's test highlights the need, identified by BARDA and the CDC, for point-of-care tests with the ability to differentiate between common and novel strains of influenza.

Important Information

This release does not reflect the views or policies, nor infer official endorsement by the CDC or the Department of Health and Human Services. MSD acknowledges the support of this project by the CDC and HHS/ASPR/BARDA.

About MSD

Meso Scale Diagnostics, LLC., based in Gaithersburg, Maryland, develops, manufactures, and markets instrumentation and assays for array-based biological measurements for research use in life sciences and for biodefense applications. MSD is currently developing products for the clinical market focused on point-of-care and high-throughput testing for influenza and other key health panels. More information about MSD and its products can be found at www.mesoscale.com or by contacting MSD at pr@mesoscale.com.


'/>"/>
SOURCE Meso Scale Diagnostics, LLC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
2. CCMR gets $2.9M for training grad students in nanoscale science
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. CCMR gets $2.9M for training grad students in nanoscale science
5. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
6. Peter Cummings to receive the 2007 AIChE Nanoscale Science and Engineering Forum Award
7. Sol-gel inks produce complex shapes with nanoscale features
8. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
9. Heavier hydrogen on the atomic scale reduces friction
10. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
11. Explosives at the microscopic scale produce shocking results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 16, 2017 , ... Recent studies show that cancer cells ... specific cancers, such as breast, prostate, or lung, target vital pathways active in ... advanced prostate cancer. , This therapy limits the production and effectiveness of ...
(Date:8/16/2017)... 16, 2017  This year,s edition of the Inc. 5000 features a ... workforce solutions, has made the list for the third year in a ... fastest-growing private companies based on a set of quantitative metrics. In addition, ... fastest-growing companies in the Bay State . ... Inc. 5000 ...
(Date:8/15/2017)... CA (PRWEB) , ... August 15, 2017 , ... ... pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch of ... number of steps needed to gain kinetic binding data for a wide range ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and The ... through a series of upcoming panels and events. The partnership culminates with the ... Hotel in New York City. , “With our experience in producing the Immuno-Oncology 360° ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):